Solara Active Pharma Sciences: Second & Final Call Notice Issued for Rights Equity Shares
Solara Active Pharma Sciences is issuing a Second and Final Call for partly paid rights equity shares. The call amount is ₹112.50 per share. The payment period is from April 23, 2026, to May 07, 2026. Trading in these partly paid shares has been suspended since April 02, 2026.
This is a crucial step for shareholders who participated in the rights issue, as failure to pay the final call can lead to forfeiture of shares. It directly impacts a specific group of shareholders and the company's capital structure.
The announcement is a procedural update regarding a rights issue call and does not contain financial results or strategic changes that would indicate a positive or negative sentiment.
Solara Active Pharma Sciences Limited has issued a Second and Final Call Money Notice to eligible partly paid rights equity shareholders. This notice, sent electronically on April 06, 2026, and physically on April 07, 2026, pertains to shares held as of the record date, April 02, 2026.
The amount due per partly paid-up equity share is ₹112.50, comprising ₹3 towards face value and ₹109.50 towards premium. The payment period for this Second and Final Call is set from April 23, 2026, to May 07, 2026, a duration of 15 days.
Shareholders can make payments through various modes, including Online ASBA, Physical ASBA, or via a 3-in-1 online trading-demat-bank account. The detailed instructions, ASBA form, and FAQs are available on the company's website and the Registrar's website. Trading in the partly paid-up equity shares (ISIN: IN9624Z01022) has been suspended effective April 02, 2026, due to this call. Failure to pay the call money may result in forfeiture of shares and deduction from future dividends.
What to do with a filing like this
Solara Active Pharma Sciences Limited filed this with the NSE as a statutory disclosure, categorised under rights issue. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Solara Active Pharma Sciences Limited. Read the original for the full detail.